Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 in Refractory or Recurrent CD30+ Hematologic Malignancies
NCT00051597Phase 2Completed
- Sponsor
- Seagen Inc.
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), large-cell lymphoma, multiple myeloma (MM), Kaposi sarcoma (KS), B cell lymphoma, sponsored by Seagen Inc.. Status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)large-cell lymphomamultiple myeloma (MM)Kaposi sarcoma (KS)B cell lymphoma
Beyond the preview
Go deeper on NCT00051597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051597.